12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Amyvid florbetapir regulatory update

EMA's CHMP issued a positive opinion recommending approval of an MAA from Eli Lilly for Amyvid florbetapir as a PET imaging agent to estimate beta amyloid neuritic plaque density in patients who...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >